This trial is active, not recruiting.

Conditions nail growth cessation, intraocular pressure
Treatments bimatoprost 0.01%, placebo: saline
Sponsor Northwestern University
Collaborator Allergan
Start date May 2015
End date June 2016
Trial size 45 participants
Trial identifier NCT02448043, STU00200526


Topical prostaglandin agents are used to help reduce eye pressure in glaucoma patients. Bimatoprost (Lumigan 0.01%) is such an agent (Allergan, Inc.). Several of our patients on bimatoprost and an observational study of patients on bimatoprost in another center reported that fingernails grew longer and became less brittle using the topical eye drops to the eyes. The purpose of the double-blinded study is to determine whether the application of the eye drops directly to the proximal nail fold of one hand using the opposite hand as a control will result in longer nails, less brittle nails, and reduced eye pressures should any of the medication be absorbed into the systemic circulation.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
(Active Comparator)
Bimatoprost 0.01% drops placed on the proximal nail folds of the randomized hand digits two times per day for 30 days.
bimatoprost 0.01% Lumigan 0.01%
Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
(Placebo Comparator)
Saline solution drops placed on the proximal nail folds of the hand digits opposite from the study hand two times per day for 30 days.
placebo: saline
Placebo drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days

Primary Outcomes

Nail growth
time frame: 30 days

Secondary Outcomes

Intraocular pressure effects
time frame: 30 days
Nail Brittleness
time frame: 30 days

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - English speaking - Normotensive or glaucoma suspects on no ocular medications - No manicure within 2 weeks of the study. Exclusion Criteria: - Individuals on topical or systemic essential fatty acids (EFA's) in hand lotions, creams, ointments, or medication, or on biotin. - Digits with signs of nail injury, deformity, or infection. - Nail biters, nail polishers, artificial nail wear or gels, and nail and trimming and filing until the study endpoint. - Women of childbearing age who are pregnant or who are trying to become pregnant. - Individuals with allergies or sensitivity to prostaglandin agents.

Additional Information

Official title Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure
Principal investigator David J Palmer, MD
Description In addition to our observations with topical bimatoprost on fingernail growth, Wand and colleagues applied bimatoprost to the base of the fingernails demonstrating a 16.9% increase in fingernail growth from baseline, and a 10.4% increase from baseline on untreated nail beds. Other than these two reports, there are no studies addressing this topic to our knowledge based on a Medline search for off-label use of this drug. Other relevant studies have addressed increased hair and eyelash growth with the prostaglandin agents. Researching the biochemistry of the relationship of prostaglandins to hair and nail growth, the final common pathway appears to be with protein kinase C and the production of tropocollagens. The dermatology literature has demonstrated that both hair and nail keratocytes reside in the nail bed suggesting that increased collagen production may enhance the growth of both the nail bed and nail plate, possibly reducing nail brittleness.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Northwestern University.